Dimensional Fund Advisors LP Reduces Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Dimensional Fund Advisors LP lowered its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 3.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 3,926,701 shares of the biopharmaceutical company’s stock after selling 125,637 shares during the period. Dimensional Fund Advisors LP’s holdings in Dynavax Technologies were worth $44,098,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Duality Advisers LP purchased a new stake in Dynavax Technologies in the 1st quarter worth about $227,000. Boston Partners bought a new position in shares of Dynavax Technologies during the first quarter valued at approximately $292,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Dynavax Technologies by 67.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 10,143 shares during the period. Choreo LLC bought a new stake in shares of Dynavax Technologies during the 2nd quarter worth approximately $363,000. Finally, Diversified Trust Co boosted its holdings in Dynavax Technologies by 3.2% during the 1st quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock valued at $367,000 after acquiring an additional 925 shares during the period. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Trading Up 1.4 %

DVAX opened at $11.00 on Monday. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $15.15. The company has a market capitalization of $1.44 billion, a P/E ratio of 183.33 and a beta of 1.37. The stock’s fifty day moving average is $11.08 and its two-hundred day moving average is $11.41. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. The firm had revenue of $73.80 million during the quarter, compared to the consensus estimate of $76.92 million. During the same period in the previous year, the company posted $0.03 earnings per share. Analysts forecast that Dynavax Technologies Co. will post 0.16 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. The Goldman Sachs Group reduced their target price on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Dynavax Technologies currently has a consensus rating of “Moderate Buy” and an average target price of $23.67.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.